Facebook
Twitter
LinkedIn
Forward
Contemporary FLASH-RT to Its Clinical Translation
FLASH radiation therapy (FLASH-RT), delivered with ultra high dose rate (UHDR), may allow patients to be treated with less normal tissue toxicity for a given tumor dose compared with currently used conventional dose rate. Clinical trials are being carried out and are needed to test whether this improved therapeutic ratio can be achieved clinically. The roadmap to the clinical translation of FLASH-RT remains yet to be clear. Gaps exist in planning, dosimetry, delivery, quality assurance technologies and credentialing processes. Recently, an NRG group has formed to report an initial framework on potential pathways to FLASH-RT trials. For this activity, experts from the NRG group elaborate on 1) current uses and the outlook for FLASH delivery technologies; 2) dosimetry, QA and credentialing requirements for FLASH trials; 3) considerations on FLASH treatment planning and bookkeeping; 4) recommendations on the design of FLASH clinical trials. We need to redefine optimization to focus not only on the dose but also on the dose rate in a manner that is robust and understandable and that can be prescribed, validated and confirmed in real time. Robust patient safety systems and access to treatment data will be critical as FLASH-RT moves into the clinical trials.
Topics:
- Flash Forward: Roadmaps to the Clinical Translation
Jeffrey Buchsbaum, MD, PhD, MS, FASTRO, AM - Proton FLASH Trials: Insights from FAST-01 and FAST-02
Anthony E. Mascia, PhD, MS - IROC Credentialing for FLASH Trials
Stephen Kry, PhD, DABR, CMQ, FAAPM - A Pathway to Bring Electron FLASH to Clinical Standard of Care
Devarati Mitra, MD, PhD - Q and A
Rongxiao Zhang, PhD
Full Panel
This activity is available from May 20, 2025, through 11:59 p.m. Eastern time on May 19, 2027.
The content was originally presented and recorded at the 2024 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, physicists, radiation therapists, radiation dosimetrists, radiation biologists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Learn about the contemporary status of FLASH-RT.
- Critically assess roadmaps to prospective FLASH trials.
- Communicate the recommendations on the design of FLASH trials.
- Rongxiao Zhang, PhD, is employed by University of Missouri and Westchester Medical Center.
- Jeffrey Buchsbaum, MD, PhD, MS, FASTRO, AM, is employed by National Cancer Institute.
- Anthony E. Mascia, PhD, MS, is employed by University of Cincinnati and UC Health. Dr. Mascia receives grant/research funding from Siemens (Varian Medical Systems).
- Stephen Kry, PhD, DABR, CMQ, FAAPM, is employed by The University of Texas MD Anderson Cancer Center. Dr. Kry receives honoraria and travel expenses from IAEA and Trans-Tasman Radiation Oncology Group.
- Devarati Mitra, MD, PhD, is employed by The University of Texas MD Anderson Cancer Center. Dr. Mitra receives grant/research funding from NCATS and RSNA.
The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until May 19, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.